Patents Examined by David A. Lambertson
  • Patent number: 6768001
    Abstract: The present invention is directed to novel xylanases (referred to as XYL-IV) and to nucleic acid molecules encoding those xylanases. Also provided herein are vectors and host cells including those nucleic acid sequences, antibodies which bind to the xylanases of the present invention, methods for producing the xylanases of the present invention, and methods employing the xylanases of the present invention.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: July 27, 2004
    Assignee: Genencor International, Inc.
    Inventors: Markku L A Saloheimo, Matti Siika-Aho, Maija Tenkanen, Merja E. Penttila
  • Patent number: 6762040
    Abstract: The invention relates to a method for increasing the copy number of a chromosomally integrated expression cassette in a microbial strain without leaving antibiotic resistance markers behind in the strain, the necessary genetic constructs, and the strains resulting from the method of the invention.
    Type: Grant
    Filed: July 5, 2001
    Date of Patent: July 13, 2004
    Assignee: Novozymes A/S
    Inventor: Michael Dolberg Rasmussen
  • Patent number: 6753151
    Abstract: Ku is a protein found in a wide range of organisms. It comprises two tightly-associated subunits termed Ku70 and Ku80. The present invention relates to the discovery and characterisation of an interaction between Ku70 and Ku80 and DNA-PKCS. Various applications based on this interaction are provided. These are relevant to numerous cellular processes which are of interest in therapeutic contexts.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: June 22, 2004
    Assignee: Kudos Pharmaceuticals Limited
    Inventors: Stephen P. Jackson, David A. Gell
  • Patent number: 6753142
    Abstract: The present invention relates generally to methods and compositions for the identification of differential protein expression patterns and concomitantly the active genetic regions that are directly or indirectly involved in different tissue types, disease states, or other cellular differences desirable for diagnosis or for targets for drug therapy.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: June 22, 2004
    Assignee: NewLink Genetics Inc.
    Inventors: Charles J. Link, Tatiana Seregina, Nicholas N. Vahanian, James N. Higginbotham, W. Jay Ramsey, Bradley J. Powers, Sachet A. Shukla, Won Bin Young
  • Patent number: 6743584
    Abstract: The invention relates to plasmids derived from pBluescript KS(+), which contains more than 1, preferably 2, 7, 14, 21 and 27, respective SK primer elements, and their use in analytical electron microscopy.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: June 1, 2004
    Assignee: Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
    Inventors: Sabine Bub, Helmut Troester, Karsten Richter, Ansgar Haking, Stefan Raddatz, Manfred Wiessler, Eberhard Spiess, Michael Trendelenburg
  • Patent number: 6737262
    Abstract: The present invention relates to an animal feed made of an amount of cereal grain and a peptide or polypeptide expressed by a transformed organism, whereby the transformed organism can be included in the animal feed composition. The present invention also relates to a method for forming the animal feed wherein the method includes forming a transformed organism by transforming a yeast cell by inserting a nucleic acid molecule which will express a polypeptide desired for use in the animal feed.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: May 18, 2004
    Inventors: Robert I. Bolla, Joseph E. Zahner, Monty S. Kerley
  • Patent number: 6737523
    Abstract: This invention provides an isolated nucleic acid comprising a PEG-3 promoter comprising the nucleotide sequence of −270 to +194 of FIG. 2. The invention also provides a method for identifying an agent that modulates PEG-3 promoter activity using a cell which comprises a PEG-3 promoter operatively linked to a reporter gene, wherein reduced reporter gene expression in the presence of the agent is indicative of an agent that inhibits PEG-3 promoter activity and wherein increased reporter gene expression in the presence of the agent is indicative of an agent that enhances PEG-3 promoter activity. The invention provides a method for treating cancer in a subject which comprises administering a nucleic acid comprising a PEG-3 promoter operatively linked to a gene-of-interest, wherein the gene-of-interest is selectively expressed in cancerous cells in the subject and such expression results in growth suppression or death of the cancerous cells.
    Type: Grant
    Filed: July 21, 2000
    Date of Patent: May 18, 2004
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Paul B. Fisher, Zao-Zhong Su
  • Patent number: 6734174
    Abstract: A protein capable of modulating or mediating the intracellular activity of RIP in inflammation, cell survival and cell death pathways is provided. DNA encoding it, a method for its production and its uses are also provided.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: May 11, 2004
    Assignees: Yeda Research and Development Co. Ltd., Albert Einstein College of Medicine of Yeshiva University
    Inventors: David Wallach, Andrei Kovalenko, Marshall S. Horwitz, Yongan Li
  • Patent number: 6709852
    Abstract: The present invention provides novel rapidly growing microorganisms and methods for their use in cloning or subcloning nucleic acid molecules. The rapid growing microorganisms of the present invention form colonies more rapidly than microorganisms typically used in molecular biology and thus provide a significant improvement in in vitro cloning methods used extensively in molecular biology. The invention also relates to kits and compositions used in the methods of the invention.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: March 23, 2004
    Assignee: Invitrogen Corporation
    Inventors: Fredric R. Bloom, Brian J. Schmidt, Jhy-Jhu Lin
  • Patent number: 6706492
    Abstract: The present invention provides a koji mold having increased protease activity and peptidase activity relative to a parent strain, a method of breeding the koji mold, and a method of manufacturing a flavor enhancer using the koji mold. More specifically, the present invention provides (1) a koji mold having increased protease activity and peptidase activity relative to a parent strain obtained by transformation using a protease gene and a peptidase gene, (2) a method of breeding the above koji mold which comprises transforming a parent strain of koji mold using a protease gene and a peptidase gene, and then selecting a transformant having higher protease activity and peptidase activity relative to a parent strain, and (3) a method of manufacturing a flavor enhancer which comprises allowing a culture product of the above koji mold to act on a protein.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: March 16, 2004
    Assignee: Kikkoman Corporation
    Inventors: Genryou Umitsuki, Hiroe Sato, Misao Sugishita, Yaichi Fukushima, Yasuji Koyama
  • Patent number: 6673894
    Abstract: An chimerical polypeptide that arrests proliferating cells in mitosis is provided. In general the polypeptide has an N-terminal transit peptide, such as HIV-1 Tat, and a C-terminal cell-cycle effector, such as a G2/M cyclin or a cytostatic factor. A polynucleotide under the control of a heterologous promoter that encodes a polypeptide that arrests cells in mitosis is also provided. The polynucleotide may, for example, encode a G2/M cyclin. Pharmaceutical compositions comprising the agent that inhibits transit through mitosis is provided. A method of treating patients suffering from a hyperplasia, such as cancer, psoriasis or benign prostate hyperplasia is provided.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: January 6, 2004
    Assignee: Nucleus Remodeling, Incorporated
    Inventor: Joseph E. Zahner
  • Patent number: 6673540
    Abstract: This invention relates to modified host cells which express heterologous fused proteins and methods of screening for test samples having peptide binding activity; wherein the modified host cell comprises: (a) a gene sequence encoding a heterologous fusion protein; the fusion protein comprising a first peptide of a peptide binding pair, or segment of the first peptide, which is joined to either a DNA binding domain or its corresponding transcriptional activation domain of a transcriptional activation protein; (b) a gene sequence encoding a heterologous fusion protein, the fusion protein comprising a second peptide of the peptide binding pair in (a), or a segment thereof, fused to either a DNA binding domain or its corresponding transcriptional activation domain, whichever one is not employed in (a); (c) a reporter gene operatively associated with the transcriptional activation protein, or a portion thereof; (d) optionally, a deletion or mutation in the chromosomal DNA of the host cell for the transcriptional a
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: January 6, 2004
    Assignee: American Cyanamid Company
    Inventors: Kathleen H. Young, Bradley A. Ozenberger
  • Patent number: 6670145
    Abstract: An improved method for detection of total coliforms and E. coli comprising a broth containing an ingredient that will encourage growth and repair of injured coliforms, buffers to maintain a pH in the range of 6.5-8, at least one agent that suppresses growth of gram positive cocci and spore-forming organisms, at least one active agent that will suppress growth of non-coliform gram negative bacteria, and at least one chromogen or fluorogen has been used effectively and is cost effective. In the preferred embodiment, both a fluorogen and chromogen were used. Preferred methods include use of filter and/or plates containing the growth-promoting ingredients and the indicators.
    Type: Grant
    Filed: August 9, 2001
    Date of Patent: December 30, 2003
    Assignee: The United States of America as represented by the Administrator of the Environmental Protection Agency
    Inventors: Kristen P. Brenner, Clifford C. Rankin, Yvette R. Roybal-McKenna, Alfred P. Dufour
  • Patent number: 6664078
    Abstract: The present invention relates to the production of biomass for the isolation of ccc plasmid DNA comprising culturing a bacterial transformant in a bioreactor containing an antibiotic-free batch medium under batch-conditions and, at the end of the batch phase, feeding under feed-back conditions the portion of a feed-back medium after the rise of the concentration of dissolved oxigen above a threshold-set point. Said feed-back medium comprises besides a carbon source a magnesium salt, preferably in concentrations above 20 mM. Preferably, the bacterial transformant is harvested after the end of the culture and frozen or freeze-dried. Also preferred is that ccc plasmid DNA is, optionally directly, isolated after harvesting the bacteria.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: December 16, 2003
    Assignee: Qiagen GmbH
    Inventors: Torsten Schmidt, Karl Friehs, Erwin Flaschel, Martin Schleef
  • Patent number: 6660851
    Abstract: A novel DNA fragment capable of enhancing the expression level of a gene. The DNA fragment according to the present invention contains a nucleotide sequence from one of the nucleotides at around positions 1- to 152 to one of the nucleotides at around positions 259 to 374 in the sequence represented by SEQ ID NO:1 and is capable of enhancing the expression level of a gene.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: December 9, 2003
    Assignee: Japan Tobacco Inc.
    Inventors: Yoshimitsu Takakura, Jun Ueki
  • Patent number: 6653111
    Abstract: The present invention provides a method for deriving an E. coli strain which produces L-theronine from E.coli strain VNIIgenetika 472T23 by transducing with bacteriophage P1 which bears a transposon.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: November 25, 2003
    Assignee: Ajinomoto Co., Inc.
    Inventors: Vladimir Georgievich Debabov, Jury Ivanovich Kozlov, Evgeny Moiseevich Khurges, Vitaly Arkadievich Livshits, Nelli Isaakovna Zhdanova, Mikhail Markovich Gusyatiner, Alexandr Konstantinovich Sokolov, Tatyana Alexandrovna Bachina, Nikolai Kazimirovich Yankovsky, Jury Dmitrievich Tsygankov, Andrei Jurievich Chistoserdov, Tatyana Grigorievna Plotnikova, Irina Olegovna Shakalis, Alla Valentinovna Belareva, Raisa Alexandrovna Arsatiants, Albert Fedorovich Sholin, Tamara Mikhailovna Pozdnyakova
  • Patent number: 6653076
    Abstract: Methods for the determination of the rate of synthesis of biopolymer synthesis and degradation in cells, tissues, or cell-free systems using monomer which as been labeled with a stable isotope are provided. Further, the present invention provides method for the determination or identification of an unknown biopolymer and for the identification of an unknown cell type, a physiological state of a cell or tissue. Also, the present invention provides a database of descriptors which can be used to define an organism, tissue type, cell type, and the like, and which database can be used in conjunction with other public and private databases to identify or characterize an organism, tissue type, cell type, state of differentiation, or physiologic state of an organism, or tissue or cell sample.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: November 25, 2003
    Assignee: The Regents of the University of Washington
    Inventors: B. Robert Franza, Jr., Yvan P. Rochon
  • Patent number: 6649595
    Abstract: Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: November 18, 2003
    Assignee: ARIAD Gene Therapeutics, Inc.
    Inventors: Timothy P. Clackson, Michael Z. Gilman, Dennis A. Holt, Terence P. Keenan, Leonard Rozamus, Wu Yang
  • Patent number: 6645739
    Abstract: The present invention provides novel expression systems for producing desired polypeptides in certain strains of yeast. The present invention further provides methods for producing polypeptide products using such expression systems. The present invention also provides compositions relating to the same.
    Type: Grant
    Filed: July 26, 2001
    Date of Patent: November 11, 2003
    Assignee: Phoenix Pharmacologies, Inc.
    Inventor: Mike A. Clark
  • Patent number: 6632671
    Abstract: The present invention generally relates to nanocapsules and methods of preparing these nanocapsules. The present invention includes a method of forming a surfactant micelle and dispersing the surfactant micelle into an aqueous composition having a hydrophilic polymer to form a stabilized dispersion of surfactant micelles. The method further includes mechanically forming droplets of the stabilized dispersion of surfactant micelles, precipitating the hydrophilic polymer to form precipitated nanocapsules, incubating the nanocapsules to reduce a diameter of the nanocapsules, and filtering or centrifuging the nanocapsules.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: October 14, 2003
    Assignee: Genesegues, Inc.
    Inventor: Gretchen M. Unger